Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

As Rocket Pharmaceuticals welcomes Dr. Mikael Dolsten from Pfizer to its Board of Directors, it's valuable to understand the financial health and market position of Pfizer (NYSE: PFE), where Dr ...

Dr. Dolsten is an accomplished industry ... curing genetic disease,” said Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development. “I am excited to bring ...

As Rocket Pharmaceuticals welcomes Dr. Mikael Dolsten from Pfizer to its Board of Directors, it's valuable to understand the financial health and market position of Pfizer (NYSE: PFE), where Dr.

“Rocket has an impressive pipeline of clinical programs which have shown tremendous promise potentially curing genetic disease,” said Dr. Mikael Dolsten, Chief Scientific Officer ...